secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001628280-24-020843
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q1 revenue $129.5M (+8.7% YoY), guides FY24 higher
------------------------------------------------------------

- Net loss from continuing ops $6.0M vs $100.0M prior year; diluted loss per share $0.07 vs $1.28.
- Pain Treatments revenue $56.7M (+23.5% US); Surgical Solutions revenue $42.3M (+19.0% US).
- Adjusted EBITDA $22.6M, up 33.5% YoY; adjusted gross margin expanded 190 bps.
- FY 2024 guidance raised: net sales $535-550M, Adj. EBITDA $94-99M, Non-GAAP EPS $0.25-0.33.
- Organic revenue growth 15.3% driven by Pain Treatments and Surgical Solutions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/0001628280-24-020843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/bvs-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-020843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer